Monday, August 11, 2014
deal with Roche
(SIX:ROG; OTCQX:RHHBY) marks the first potential exit for early stage life science venture
fund AmorChem and its in-house medicinal chemistry CRO,
NuChem Therapeutics Inc.
gives Roche an option for an
exclusive, worldwide license to therapies for myotonic dystrophy 1 (Steinert disease)
at the end of the collaboration. In total, AmorChem can collect $107 million
with development and commercial milestones, plus single-digit tiered royalties.